A Phase 3 Randomized Study Comparing Talquetamab SC in Combination With Daratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination With Daratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexamethasone (DPd), in Participants With Relapsed or Refractory Multiple Myeloma who Have Received at Least 1 Prior Line of Therapy

About this Study
Sponsor Protocol ID:64407564MMY3002
IRB Number:2023-72
Actively Enrolling
Interventional
Phase 3
November 20, 2023
Eligibility Criteria
18 years old
Both Male and Female
Yes
No
No
Categories Click category to view its trials.
Cancer
Participating Locations
Cancer Center and Research Institute clinics
University Hospital - UMMC
Contact Information
Contact Name: Jennifer Barnes
Phone Number: 601-815-4540
Email: jbarnes@umc.edu
Principal Investigator:Stephanie Elkins
How to participate in our Clinical Trials